Shandong Simcere-Medgenn Bio-Pharmaceuticals

Shandong Simcere-Medgenn Bio-Pharmaceuticals is a specialized biopharmaceutical subsidiary of Simcere Pharmaceutical Group, based in Yantai, China. The company is primarily recognized for the development and commercialization of Endostar (recombinant human endostatin), a novel anti-angiogenic therapy for the treatment of non-small cell lung cancer. Originally founded as Medgenn, the company was acquired by Simcere in 2006 to bolster its oncology biologics portfolio. The Yantai facility operates as a major manufacturing base, adhering to high-standard GMP requirements for the production of recombinant proteins. Beyond its lead product, the company supports clinical research into expanded indications for endostatin and other biological candidates within the Simcere pipeline.